Next Article in Journal
Incidence and Associated Factors of SARS-CoV-2 Infection Post-mRNA-1273 Booster Vaccination in Health-Care Workers
Previous Article in Journal
Yeast-Based Virus-like Particles as an Emerging Platform for Vaccine Development and Delivery
Previous Article in Special Issue
Neutralizing Antibodies to Human Cytomegalovirus Recombinant Proteins Reduce Infection in an Ex Vivo Model of Developing Human Placentas
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 11
Issue 2
10.3390/vaccines11020480
vaccines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Assessment of the Interferon-Lambda-3 Polymorphism in the Antibody Response to COVID-19 in Older Adults Seropositive for CMV

by
Ariane Nardy
1,*,
Camila Tussato Soares Camargo
1,
Yasmim Faustina Castro de Oliveira
1,
Fernanda Cristina da Silva
1,
Millena Soares de Almeida
1,
Fernanda Rodrigues Monteiro
2,
Brenda Rodrigues Silva
2,
Jônatas Bussador do Amaral
3,
Danielle Bruna Leal Oliveira
4,5,
Edison Luiz Durigon
5,6,
Guilherme Pereira Scagion
5,
Vanessa Nascimento Chalup
5,
Érika Donizetti Candido
5,
Andressa Simões Aguiar
5,7,
Neil Ferreira Novo
2,
Marina Tiemi Shio
2,
Carolina Nunes França
2,
Luiz Henrique da Silva Nali
2 and
André Luis Lacerda Bachi
2
1
Faculty of Pharmacy, Campus, Santo Amaro University, São Paulo 04829-300, Brazil
2
Post-Graduation Program in Health Sciences, Santo Amaro University (UNISA), São Paulo 04829-300, Brazil
3
ENT Research Laboratory, Department of Otorhinolaryngology—Head and Neck Surgery, Federal University of Sao Paulo (UNIFESP), São Paulo 04021-001, Brazil
4
Hospital Israelita Albert Einstein, São Paulo 05652-900, Brazil
5
Laboratory of Clinical and Molecular Virology, Department of Microbiology, Institute of Biomedical Science, University of São Paulo, São Paulo 05508-060, Brazil
6
Scientific Platform Pasteur, University of São Paulo, São Paulo 05508-060, Brazil
7
Infection Control Service, São Luiz Gonzaga Hospital of Santa Casa de Misericordia of São Paulo, São Paulo 02276-140, Brazil
*
Author to whom correspondence should be addressed.
Vaccines 2023, 11(2), 480; https://doi.org/10.3390/vaccines11020480
Submission received: 15 January 2023 / Revised: 9 February 2023 / Accepted: 10 February 2023 / Published: 18 February 2023
(This article belongs to the Special Issue The Interaction of Cytomegalovirus with the Human Immune System)
Browse Figures
Review Reports Versions Notes

Abstract

Background: Here, we investigated the impact of IFN-lambda-3 polymorphism on specific IgG responses for COVID-19 in older adults seropositive for CMV. Methods: Blood samples of 25 older adults of both sexes were obtained at three different times: during a micro-outbreak (MO) of SARS-CoV-2 in 2020; eight months after (CURE); and 30 days after the administration of the second dose of ChadOx-1 vaccine (VAC). The specific IgG for both SARS-CoV-2 and CMV antigens, neutralizing antibodies against SARS-CoV-2, and also the polymorphism profile for IFN-lambda-3 (rs12979860 C > T) were assessed. Results: Higher levels of specific IgG for SARS-CoV-2 antigens were found in the MO and VAC than in the CURE time-point. Volunteers with specific neutralizing antibodies against SARS-CoV-2 showed better specific IgG responses for SARS-CoV-2 and lower specific IgG levels for CMV than volunteers without specific neutralizing antibodies. Significant negative correlations between the specific IgG levels for SARS-CoV-2 and CMV were found at the MO time-point, as well as in the group of individuals homozygous for allele 1 (C/C) in the MO time-point and heterozygotes (C/T) in the CURE time-point. Conclusion: Our results suggested that both CMV seropositivity and the homozygosis for allele 1 (C/C) in IFN-lambda-3 gene can negatively impact the antibody response to COVID-19 infection and vaccination in older adults.
Keywords: cytomegalovirus; SARS-CoV-2; immunoglobulins; neutralizing antibody; outbreak; allele cytomegalovirus; SARS-CoV-2; immunoglobulins; neutralizing antibody; outbreak; allele

Share and Cite

MDPI and ACS Style

Nardy, A.; Camargo, C.T.S.; Oliveira, Y.F.C.d.; Silva, F.C.d.; Almeida, M.S.d.; Monteiro, F.R.; Silva, B.R.; Amaral, J.B.d.; Oliveira, D.B.L.; Durigon, E.L.; et al. Assessment of the Interferon-Lambda-3 Polymorphism in the Antibody Response to COVID-19 in Older Adults Seropositive for CMV. Vaccines 2023, 11, 480. https://doi.org/10.3390/vaccines11020480

AMA Style

Nardy A, Camargo CTS, Oliveira YFCd, Silva FCd, Almeida MSd, Monteiro FR, Silva BR, Amaral JBd, Oliveira DBL, Durigon EL, et al. Assessment of the Interferon-Lambda-3 Polymorphism in the Antibody Response to COVID-19 in Older Adults Seropositive for CMV. Vaccines. 2023; 11(2):480. https://doi.org/10.3390/vaccines11020480

Chicago/Turabian Style

Nardy, Ariane, Camila Tussato Soares Camargo, Yasmim Faustina Castro de Oliveira, Fernanda Cristina da Silva, Millena Soares de Almeida, Fernanda Rodrigues Monteiro, Brenda Rodrigues Silva, Jônatas Bussador do Amaral, Danielle Bruna Leal Oliveira, Edison Luiz Durigon, and et al. 2023. "Assessment of the Interferon-Lambda-3 Polymorphism in the Antibody Response to COVID-19 in Older Adults Seropositive for CMV" Vaccines 11, no. 2: 480. https://doi.org/10.3390/vaccines11020480

APA Style

Nardy, A., Camargo, C. T. S., Oliveira, Y. F. C. d., Silva, F. C. d., Almeida, M. S. d., Monteiro, F. R., Silva, B. R., Amaral, J. B. d., Oliveira, D. B. L., Durigon, E. L., Scagion, G. P., Chalup, V. N., Candido, É. D., Aguiar, A. S., Novo, N. F., Shio, M. T., França, C. N., Nali, L. H. d. S., & Bachi, A. L. L. (2023). Assessment of the Interferon-Lambda-3 Polymorphism in the Antibody Response to COVID-19 in Older Adults Seropositive for CMV. Vaccines, 11(2), 480. https://doi.org/10.3390/vaccines11020480

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop